Dec 6 (Reuters) - European Medicines Agency (EMA):

* EMA RECOMMENDS APPROVAL FOR USE OF ROACTEMRA IN ADULTS WITH SEVERE COVID-19: 06/12/2021

* SAFETY PROFILE OF MEDICINE FAVOURABLE IN THOSE RECEIVING TREATMENT WITH CORTICOSTEROIDS, CONCLUDED MEDICINE'S BENEFITS GREATER THAN RISKS FOR THESE PATIENTS

* RECOMMENDED EXTENDING TOCILIZUMAB INDICATION FOR TREATMENT OF ADULTS WITH COVID ON SYSTEMIC TREATMENT WITH CORTICOSTEROIDS AND NEED OXYGEN SUPPORT Further company coverage: